Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $501,079.15 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,005 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $27.83, for a total transaction of $501,079.15. Following the completion of the sale, the chief financial officer directly owned 270,046 shares of the company’s stock, valued at $7,515,380.18. This trade represents a 6.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.96, for a total transaction of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.98, for a total transaction of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78.

Hims & Hers Health Stock Down 2.7%

Shares of NYSE:HIMS opened at $28.95 on Thursday. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a 50 day moving average of $20.45 and a two-hundred day moving average of $31.74. The company has a market capitalization of $6.60 billion, a price-to-earnings ratio of 56.77, a price-to-earnings-growth ratio of 2.83 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter last year, the company earned $0.11 earnings per share. Hims & Hers Health’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of Hims & Hers Health by 0.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after buying an additional 200 shares in the last quarter. GAMMA Investing LLC lifted its stake in Hims & Hers Health by 6.1% during the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after purchasing an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC lifted its stake in Hims & Hers Health by 1.8% during the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after purchasing an additional 252 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after purchasing an additional 283 shares during the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co lifted its stake in Hims & Hers Health by 4.8% during the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock worth $436,000 after purchasing an additional 350 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday, March 10th. Evercore set a $24.00 price target on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Monday, March 9th. Bank of America raised their price target on shares of Hims & Hers Health from $21.00 to $25.00 and gave the stock a “neutral” rating in a research report on Thursday, April 16th. Finally, TD Cowen decreased their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $31.86.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Pipeline & partner speculation — Momentum behind HIMS has been driven by reports of FDA peptide news and a potential partnership with Novo Nordisk, which traders say helped push the stock higher as investors price in new commercial opportunities. Read More.
• Positive Sentiment: Product expansion — HIMS announced it will offer perimenopause/menopause treatment options (including estrogen patch access) on its telehealth platform, expanding addressable market and recurring-care use cases. This is a direct revenue opportunity and supports the company’s DTC care‑platform narrative. Read More.
• Neutral Sentiment: Sector/flow dynamics — Broader small‑cap biotech and telehealth sector enthusiasm (positive clinical results at peers, flow into health names) has amplified HIMS moves even where company‑specific catalysts are limited. That can accelerate swings up or down ahead of earnings. Read More.
• Neutral Sentiment: Analyst & institutional backdrop — Coverage is mixed: consensus is a “Hold” with a mid‑$30s/low‑$20s range of targets and heavy institutional ownership (~63%). Upgrades/target changes have helped sentiment but don’t fully resolve execution risk.
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders have sold sizable blocks recently under pre‑arranged Rule 10b5‑1 plans (April filings). While 10b5‑1 execution mutes signaling, the volume and timing can weigh on near‑term sentiment. Read More. Read More.
• Negative Sentiment: Competitive threat — Amazon’s launch of a GLP‑1 weight‑loss program highlights new, deep-pocketed competition in a key monetizable category for HIMS (weight‑loss/medication access + ongoing care). That announcement pressured the stock amid concerns about margin compression and customer share loss. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.